Shots:

• Sandoz launches Symjepi (epinephrine- 0.3mg & 0.15mg) injection for the emergency treatment of Type 1 allergic reactions including anaphylaxis and will be available in adult and pediatric doses at pharmacy retail outlets in the US
• The launch of Symjepi will address ongoing epinephrine auto-injector shortage- meeting the demands of patients with type 1 allergic reactions leading to death if left untreated
• Symjepi is a single-dose- pre-filled syringe and device combination available as a cost-effective treatment option with a compact and user-friendly design for Type 1 including anaphylaxis to stinging and biting insects- allergen immuno-therapy- foods- drugs- diagnostic testing substances

Click here to read full press release/ article | Ref: Sandoz | Image: Snack Safely